NCT07091695View on ClinicalTrials.gov

Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab

Not yet recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

September 1, 2025

Study Completion Date

October 1, 2025

Conditions
Melanoma
Interventions
BIOLOGICAL

Nivolumab + relatlimab

As prescribed by the treating clinician

BIOLOGICAL

Nivolumab + ipilimumab

As prescribed by the treating clinician

Trial Locations (1)

43017

Cardinal Health, Dublin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY